Cargando…

Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection

OBJECTIVES: To evaluate the pharmacokinetics and clinical effectiveness of IV and oral fosfomycin treatment in patients with recurrent urinary tract infection (rUTI) with Escherichia coli. PATIENTS AND METHODS: Patients with rUTI treated with 3 g of oral fosfomycin every 72 h for at least 14 days we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuiper, Sander G, Dijkmans, Anneke C, Wilms, Erik B, Kamerling, Ingrid M C, Burggraaf, Jacobus, Stevens, Jasper, van Nieuwkoop, Cees
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297308/ https://www.ncbi.nlm.nih.gov/pubmed/32712666 http://dx.doi.org/10.1093/jac/dkaa294

Ejemplares similares

Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens
por: Ortiz Zacarías, Natalia V., et al.
Publicado: (2018)

Fosfomycin: Pharmacological, Clinical and Future Perspectives
por: Dijkmans, Anneke Corinne, et al.
Publicado: (2017)

Serum and Prostatic Tissue Concentrations of Cefazolin, Ciprofloxacin and Fosfomycin after Prophylactic Use for Transurethral Resection of the Prostate
por: Sobels, Annemieke, et al.
Publicado: (2022)

The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL‐17822 in healthy male volunteers
por: Goulooze, Sebastiaan C., et al.
Publicado: (2020)

The Oral Pheneticillin Absorption Test: An Accurate Method to Identify Patients with Inadequate Oral Pheneticillin Absorption
por: Dijkmans, Anneke C., et al.
Publicado: (2019)

Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial( )
por: ten Doesschate, Thijs, et al.
Publicado: (2021)

Deciphering pharmacokinetics and pharmacodynamics of fosfomycin
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2019)

Oral and intravenous fosfomycin in complicated urinary tract infections
por: López-Montesinos, Inmaculada, et al.
Publicado: (2019)

Susceptibility of Escherichia coli from Community-Acquired Urinary Tract Infection to Fosfomycin, Nitrofurantoin, and Temocillin in Korea
por: Seo, Mi-Ran, et al.
Publicado: (2014)

Antimicrobial Susceptibilities of Urinary Extended-spectrum β-lactamase Escherichia coli to Fosfomycin
por: Saeed, Nermin Kamal, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Analysis of Oral Calcium Fosfomycin: Are Urine Levels Sufficient to Ensure Efficacy for Urinary Tract Infections?
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2023)

611. Fosfomycin Resistance of Multidrug-Resistant Escherichia coli and Mechanisms of Fosfomycin Resistance
por: Seok, Hyeri, et al.
Publicado: (2019)

Fosfomycin for management of persistent female lower urinary tract infection
por: Joob, Beuy, et al.
Publicado: (2018)

Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections
por: Zhanel, George G., et al.
Publicado: (2020)

Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST)
por: ten Doesschate, Thijs, et al.
Publicado: (2018)

Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial
por: Sojo-Dorado, Jesús, et al.
Publicado: (2022)

Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study
por: Matthews, Philippa C., et al.
Publicado: (2016)

Fosfomycin Resistance in Escherichia coli, Pennsylvania, USA
por: Alrowais, Hind, et al.
Publicado: (2015)

Plasma and Urine Pharmacokinetics of Oral Fosfomycin Tromethamine in Dogs
por: Jariyapamornkoon, Nattha, et al.
Publicado: (2023)

Urinary Pharmacokinetic and Pharmacodynamic Profiles of Fosfomycin against Extended-Spectrum β-Lactamase-Producing Escherichia coli with Canine Ex Vivo Modeling: A Pilot Study
por: Harada, Kazuki, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario
por: Perrault, Louise, et al.
Publicado: (2017)

An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
por: Vrouwe, Josephina P. M., et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model
por: Zykov, Ilya Nikolaevich, et al.
Publicado: (2018)

A Comparative Study of Urinary Tests and Cultures for the Effectiveness of Fosfomycin in Catheter-Related Urinary Tract Infections
por: Jo, Jung Ki, et al.
Publicado: (2022)

Effect of Glycerol on Fosfomycin Activity against Escherichia coli
por: Ortiz-Padilla, Miriam, et al.
Publicado: (2022)

Bacterial sensitivity to fosfomycin in pregnant women with urinary infection
por: Souza, Rodrigo Batista, et al.
Publicado: (2015)

IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis
por: Kane, Zoe, et al.
Publicado: (2021)

Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum β-lactamase-production in urinary isolates of Escherichia coli
por: Ríos, Esther, et al.
Publicado: (2022)

Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial
por: Gágyor, Ildikó, et al.
Publicado: (2015)

Multiple-Dose Oral Fosfomycin for Treatment of Complicated Urinary Tract Infections in the Outpatient Setting
por: Derington, Catherine G, et al.
Publicado: (2020)

Fosfomycin Resistance in Escherichia coli Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics
por: Seok, Hyeri, et al.
Publicado: (2020)

Mechanism of Reduced Susceptibility to Fosfomycin in Escherichia coli Clinical Isolates
por: Ohkoshi, Yasuo, et al.
Publicado: (2017)

Novel Chromosomal Mutations Responsible for Fosfomycin Resistance in Escherichia coli
por: Cattoir, Vincent, et al.
Publicado: (2020)

Resensitization of Fosfomycin-Resistant Escherichia coli Using the CRISPR System
por: Walflor, Haniel Siqueira Mortagua, et al.
Publicado: (2022)

1526. Oral Fosfomycin Use for Urinary Tract Infections and Its Clinical Impact on Hospital Stay
por: Mai, Christina, et al.
Publicado: (2018)

Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales
por: Bouiller, Kévin, et al.
Publicado: (2022)

Real-Life Comparison of Fosfomycin to Nitrofurantoin for the Treatment of Uncomplicated Lower Urinary Tract Infection in Women
por: Shafrir, Asher, et al.
Publicado: (2023)

Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort Study
por: Wald-Dickler, Noah, et al.
Publicado: (2021)

Treatment Duration of Febrile Urinary Tract Infections
por: van der Starre, Willize E., et al.
Publicado: (2011)

Remarkable Pharmacokinetics of Monoclonal Antibodies: A Quest for an Explanation
por: Reijers, Joannes A. A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2qvg65pcrit66h8f6a97o7868d